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1. INTRODUCTION {#agm212005-sec-0006}
===============

MicroRNAs (miRNAs) are a new class of small non‐coding, single‐stranded RNA molecules with approximately 23 nucleotides in length, and they could pair to complementary sequences in the 3′ untranslated region (3′ UTR) of target mRNAs.[1](#agm212005-bib-0001){ref-type="ref"} Functionally, the miRNAs can not only regulate gene expression but also involve in diverse cellular biological processing, including differentiation, proliferation, growth, apoptosis, migration, and survival.[1](#agm212005-bib-0001){ref-type="ref"} Each miRNA can affect a variety of mRNAs, depending on its targets, and can play different roles in biological or pathological processes.[2](#agm212005-bib-0002){ref-type="ref"} The miR‐200 family of miRNAs is composed of miR‐200a, miR‐200b, miR‐200c, miR‐141, and miR‐429, which are located in two different clusters: miR‐200a, miR‐200b, and miR‐429 on chromosome 1, miR‐200c and miR‐141 on chromosome 12.[3](#agm212005-bib-0003){ref-type="ref"} Recent studies have demonstrated that miR‐200 families play significant roles in human various cancers, such as lung cancer, gastric cancer, colorectal cancer, ovarian cancer, breast cancer, and glioma.[4](#agm212005-bib-0004){ref-type="ref"}, [5](#agm212005-bib-0005){ref-type="ref"}, [6](#agm212005-bib-0006){ref-type="ref"}, [7](#agm212005-bib-0007){ref-type="ref"}, [8](#agm212005-bib-0008){ref-type="ref"}, [9](#agm212005-bib-0009){ref-type="ref"}, [10](#agm212005-bib-0010){ref-type="ref"}, [11](#agm212005-bib-0011){ref-type="ref"}, [12](#agm212005-bib-0012){ref-type="ref"}, [13](#agm212005-bib-0013){ref-type="ref"}

To date, some studies have investigated that downregulation of miR‐200 family correlated with progressive pathological feature and poor prognosis in cancer patients.[2](#agm212005-bib-0002){ref-type="ref"}, [4](#agm212005-bib-0004){ref-type="ref"}, [5](#agm212005-bib-0005){ref-type="ref"}, [6](#agm212005-bib-0006){ref-type="ref"} However, some others showed insignificant or opposite results.[1](#agm212005-bib-0001){ref-type="ref"}, [7](#agm212005-bib-0007){ref-type="ref"}, [8](#agm212005-bib-0008){ref-type="ref"}, [9](#agm212005-bib-0009){ref-type="ref"}, [10](#agm212005-bib-0010){ref-type="ref"}, [11](#agm212005-bib-0011){ref-type="ref"}, [12](#agm212005-bib-0012){ref-type="ref"}, [13](#agm212005-bib-0013){ref-type="ref"} According to this, it remains unclear whether miRNA‐200 families act as tumor suppressors or oncogenes in human malignancies and the prognostic significance.[14](#agm212005-bib-0014){ref-type="ref"} Thus, the prognostic value of miR‐200 family in patients with various carcinomas remains controversial. In terms of the limits of the single study, we performed this meta‐analysis of all eligible studies to discuss the relationship between miR‐200 family and prognosis in human malignant neoplasms.

2. MATERIALS AND METHODS {#agm212005-sec-0007}
========================

2.1. Search strategy {#agm212005-sec-0008}
--------------------

We searched online in PubMed, EMBASE, and CNKI databases up to October 18, 2016, to identify relevant studies, with a combination of the following keywords used simultaneously, namely "cancer," "carcinoma," "tumor," "micro‐RNA‐200 family," "miRNA‐200," "miR‐200," "hazard ratio (HR)," "follow‐up," "survival," and "prognosis." We evaluated potentially relevant studies by examining their titles, abstracts, and full texts matching the eligible criteria retrieved.

Studies were considered eligible if they met the following criteria: (i) studies focused on patients with any type of cancers; (ii) studies measuring the expression of miR‐200 family in tissue or serum/plasma; (iii) studies investigating the association between miR‐200 family expression and prognosis outcomes. Articles were excluded if they were review articles or letters, not focusing on human carcinomas. Other exclusion criteria included studies lacking key information such as HR, 95% confidence intervals (CIs), and *P* value, without survival curves.

2.2. Data extraction {#agm212005-sec-0009}
--------------------

We extracted relevant data from included studies and recorded these data based on a standardized form. Extracted data elements included: (i) the name of first author and publication year; (ii) characteristics of the studied population, including total number of patients, country, ethnicity, cancer type, and sample category; (iii) test method; (iv) study design; (v) cutoff value; (vi) follow‐up time; (vii) HRs of elevated miR‐200 family expression for OS, PFS, and RFS, along with their 95% CIs and *P* values. If HRs and 95% CIs were not directly reported, data would be extracted from Kaplan‐Meier curves of graphical survival plots to calculate HRs and 95% CIs.[15](#agm212005-bib-0015){ref-type="ref"} The extracted information was summarized in a consistent manner to prevent bias.

2.3. Statistical methods {#agm212005-sec-0010}
------------------------

The aggregation of HRs and 95% CIs was calculated in the following Tierney method.[16](#agm212005-bib-0016){ref-type="ref"} Forest plots were used to estimate the effect of miR‐200 family expression on patients' survival. A test of heterogeneity among included studies was carried out using Cochran Q test and Higgins *I*‐squared statistic. If *P *\<* *.1 and the percentage of *I* ^*2*^ \> 50%, then random‐effects model (Der Simonian and Laird method) was adopted, otherwise, the fixed‐effects model (Mantel‐Haenszel test) was used.[17](#agm212005-bib-0017){ref-type="ref"} Subgroup analysis was performed by the ethnicity, cancer type, and miRNA type method. Publication bias was assessed by Egger\'s linear regression test with a funnel plot.[18](#agm212005-bib-0018){ref-type="ref"} For all analyses, a *P* value \<.05 was considered to be statistically significant, and all the *P* values were two‐sided. All analyses were performed with the STATA 11.0 software (Stata Corp LP, College Station, TX, USA).

3. RESULTS {#agm212005-sec-0011}
==========

A total of 274 potentially relevant studies were identified from literature search in PubMed, EMBASE and CNKI databases; 257 papers were excluded after manual screening of titles, abstracts and key words, because they were not related to the current study. After reading the full texts of the remaining 17 studies, 12 eligible studies were included for the final analysis. A flow diagram of the study selection process is shown in Figure [1](#agm212005-fig-0001){ref-type="fig"}.

![Flow diagram of the study selection process](AGM2-1-39-g001){#agm212005-fig-0001}

We collected data from enrolled 12 retrospective studies. Ten of these studies examined cancerous tissue, and only two did with serum or plasma. The expression level of miR‐200 was widely detected by quantitative real‐time polymerase chain reaction (qRT‐PCR) assay. The cutoff values of miR‐200 family were different in each study, such as median, mean, quintile, or twofold. The main characteristics of analyzed studies are systematically listed in Table [1](#agm212005-tbl-0001){ref-type="table"}. For prognosis, all the studies analyzed OS and significant heterogeneity between studies was shown (*P *\<* *.001, *I* ^*2*^ * *= 79%); hence, a random‐effects model was applied to estimate a pooled HR (HR = 1.54) along with its 95% CI (1.01‐2.33). We found that higher expression of miR‐200 family significantly associated with poorer OS. Three studies evaluated PFS or RFS, and the results indicated that there was no statistical association (Table [2](#agm212005-tbl-0002){ref-type="table"}; Figure [2](#agm212005-fig-0002){ref-type="fig"} ).

###### 

Main characteristics of all studies included in the meta‐analysis

  Author & Year    Country   Ethnicity   N     Study design   Cancer type   Cutoff     Method       Sample   Follow‐up (mo)   miR type   Survival
  ---------------- --------- ----------- ----- -------------- ------------- ---------- ------------ -------- ---------------- ---------- ----------
  Tejero 2014      Spain     Caucasian   155   R              Lung          NG         qRT‐PCR      Tissue   43 (2‐160)       miR‐200c   OS
  Cao 2014         China     Asian       100   R              Ovarian       Median     qRT‐PCR      Tissue   36.8 (6‐56)      miR‐200a   OS
  Cao 2014         China     Asian       100   R              Ovarian       Median     qRT‐PCR      Tissue   36.8 (6‐56)      miR‐200b   OS
  Cao 2014         China     Asian       100   R              Ovarian       Median     qRT‐PCR      Tissue   36.8 (6‐56)      miR‐200c   OS
  Men 2014         China     Asian       168   R              Glioma        Median     qRT‐PCR      Tissue   60               miR‐200b   OS
  DIAZ 2014        Spain     Caucasian   127   R              Colorectal    NG         qRT‐PCR      Tissue   120              miR‐200a   OS
  DIAZ 2014        Spain     Caucasian   127   R              Colorectal    NG         qRT‐PCR      Tissue   120              miR‐200c   OS
  DIAZ 2014        Spain     Caucasian   127   R              Colorectal    NG         qRT‐PCR      Tissue   120              miR‐429    OS
  Toiyama 2013     Japan     Asian       182   R              Colorectal    NG         qRT‐PCR      Serum    60               miR‐200c   OS
  Leskela 2011     Spain     Caucasian   72    R              Ovarian       NG         qRT‐PCR      Tissue   128              miR‐429    OS
  Ayerbes 2012     Spain     Caucasian   52    R              Gastric       Mean       qRT‐PCR      Serum    26.3 (6‐53)      miR‐200c   OS
  Hu 2009          China     Asian       55    R              Ovarian       NG         qRT‐PCR      Tissue   50               miR‐200a   OS
  Song 2013        China     Asian       180   R              Gastric       Quintile   Microarray   Tissue   35 (1‐112)       miR‐200a   OS
  Song 2013        China     Asian       180   R              Gastric       Quintile   Microarray   Tissue   35 (1‐112)       miR‐200b   OS
  Song 2013        China     Asian       180   R              Gastric       Quintile   Microarray   Tissue   35 (1‐112)       miR‐200c   OS
  Liu 2012         China     Asian       70    R              Lung          Twofold    qRT‐PCR      Tissue   24               miR‐141    OS
  Liu 2012         China     Asian       70    R              Lung          Twofold    qRT‐PCR      Tissue   24               miR‐200c   OS
  Tuomarila 2014   Finland   Caucasian   172   R              Breast        Median     qRT‐PCR      Tissue   240              miR‐200c   OS
  Li 2012          China     Asian       107   R              Colorectal    NG         qRT‐PCR      Tissue   65 (11‐82)       miR‐429    OS
  Men 2014         China     Asian       168   R              Glioma        Median     qRT‐PCR      Tissue   60               miR‐200b   PFS
  Ayerbes 2012     Spain     Caucasian   52    R              Gastric       Mean       qRT‐PCR      Serum    26.3 (6‐53)      miR‐200c   PFS
  Song 2013        China     Asian       180   R              Gastric       Quintile   Microarray   Tissue   35 (1‐112)       miR‐200a   PFS
  Song 2013        China     Asian       180   R              Gastric       Quintile   Microarray   Tissue   35 (1‐112)       miR‐200b   PFS
  Song 2013        China     Asian       180   R              Gastric       Quintile   Microarray   Tissue   35 (1‐112)       miR‐200c   PFS
  Leskela 2011     Spain     Caucasian   72    R              Ovarian       NG         qRT‐PCR      Tissue   128              miR‐429    RFS
  Leskela 2011     Spain     Caucasian   72    R              Ovarian       NG         qRT‐PCR      Tissue   128              miR‐200c   RFS
  Leskela 2011     Spain     Caucasian   72    R              Ovarian       NG         qRT‐PCR      Tissue   128              miR‐141    RFS
  Hu 2009          China     Asian       55    R              Ovarian       NG         qRT‐PCR      Tissue   50               miR‐200a   RFS
  Tuomarila 2014   Finland   Caucasian   172   R              Breast        Median     qRT‐PCR      Tissue   240              miR‐200c   RFS

N, number of patients; R, retrospective; qRT‐PCR, quantitative real‐time PCR; OS, overall survival; PFS, progression‐free survival; RFS, recurrence‐free survival; CI, confidence interval; NG, not given.
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###### 

Patient survival by total and stratified analyses

  Subgroup                OS   PFS                                                         RFS                                                                                                                                             
  ----------------------- ---- ----------------------------------------------------------- -------- ---- ---------------------------------------------------------- ------ ---- ---------------------------------------------------------- --------
  Overall                 19   1.54 (1.01‐2.33)[a](#agm212005-note-0003){ref-type="fn"}    .044     5    0.92 (0.67‐1.26)[a](#agm212005-note-0003){ref-type="fn"}   .582   5    0.65 (0.29‐1.48)[a](#agm212005-note-0003){ref-type="fn"}   .307
  Ethnicity                                                                                                                                                                                                                                
  Caucasian               7    0.94 (0.46‐1.91)[a](#agm212005-note-0003){ref-type="fn"}    .862     1    --                                                         --     4    0.74 (0.28‐2.01)[a](#agm212005-note-0003){ref-type="fn"}   .559
  Asian                   12   2.19 (1.27‐3.78)[a](#agm212005-note-0003){ref-type="fn"}    .005     4    0.82 (0.65‐1.02)[a](#agm212005-note-0003){ref-type="fn"}   .080   1    --                                                         --
  Cancer type                                                                                                                                                                                                                              
  Lung                    3    3.09 (1.75‐5.46)[b](#agm212005-note-0004){ref-type="fn"}    \<.001   --   --                                                         --     --   --                                                         --
  Gastric or Colorectal   9    1.00 (0.67‐1.50)[a](#agm212005-note-0003){ref-type="fn"}    .992     4    0.95 (0.67‐1.33)[a](#agm212005-note-0003){ref-type="fn"}   .745   --   --                                                         --
  Ovarian                 5    3.49 (0.47‐25.62)[a](#agm212005-note-0003){ref-type="fn"}   .220     --   --                                                         --     4    0.43 (0.29‐0.66)[a](#agm212005-note-0003){ref-type="fn"}   \<.001
  Others                  2    1.63 (0.40‐6.69)[a](#agm212005-note-0003){ref-type="fn"}    .498     1    --                                                         --     1    --                                                         --
  miRtype                                                                                                                                                                                                                                  
  miR‐200a                4    1.03 (0.28‐3.82)[a](#agm212005-note-0003){ref-type="fn"}    .961     1    --                                                         --     1    --                                                         --
  miR‐200b                3    1.83 (0.44‐7.65)[a](#agm212005-note-0003){ref-type="fn"}    .406     2    0.79 (0.55‐1.14)[a](#agm212005-note-0003){ref-type="fn"}   .213   --   --                                                         --
  miR‐200c                8    2.25 (1.39‐3.64)[a](#agm212005-note-0003){ref-type="fn"}    .001     2    1.28 (0.79‐2.09)[a](#agm212005-note-0003){ref-type="fn"}   .314   2    1.20 (0.18‐8.09)[a](#agm212005-note-0003){ref-type="fn"}   .854
  miR‐429                 3    0.69 (0.22‐2.17)[a](#agm212005-note-0003){ref-type="fn"}    .522     --   --                                                         --     1    --                                                         --
  miR‐141                 1    --                                                          --       --   --                                                         --     1    --                                                         --

OS, overall survival; PFS, progression‐free survival; RFS, recurrence‐free survival; HR, hazard ratio; CI, confidence interval.

The HRs and 95% CIs of analyzed studies were pooled by the random‐effects model if the *P* value for heterogeneity was \<.10 or *I* ^*2*^ was \>50%.

The HRs and 95% CIs of analyzed studies were pooled by the fixed‐effects model if the *P* value for heterogeneity was more than .10 or *I* ^*2*^ was \<50%.
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![Forest plots of total analyses for patient survival associated with miR‐200 family expression. The squares and horizontal lines correspond to study‐specific hazard ratio (HR) and 95% confidence interval (CI). The area of the squares reflects the weight. The diamond represents HR and 95% CI](AGM2-1-39-g002){#agm212005-fig-0002}

Furthermore, stratified analyses were performed, such as ethnicity, cancer type, and miRNA type. Firstly, for ethnicity, seven studies in Asian subgroup investigated that elevated miR‐200 family significantly predicted poor survival (HR = 2.19, 95% CI 1.27‐3.78) by a random‐effects model (*P *\<* *.001, *I* ^*2*^ = 78%), and the other five studies in Caucasian subgroup could not show a significant association between miR‐200 family and Caucasian cases (HR = 0.94, 95% CI 0.46‐1.91). Secondly, for cancer type, two studies in lung carcinoma subgroup displayed a worse survival outcome linked to the elevated miR‐200 family (HR = 3.09, 95% CI 1.75‐5.46) using a fixed‐effects model (*P *=* *.60, *I* ^*2*^ * *\< 0). And in other subgroups of gastric or colorectal cancer, ovarian cancer, breast cancer, and glioma, there was no obviously significant association with poor survival (HR = 1.00, 95% CI 0.67‐1.50; HR = 3.49, 95% CI 0.47‐25.62; HR = 1.63, 95% CI 0.40‐6.69, respectively). In addition, for miRNA type, eight studies also indicated that high miR‐200c expression was a significant predictor for worse outcome (HR = 2.25, 95% CI 1.39‐3.64). No significant association was found in miR‐200a, miR‐200b, and miR‐429 subgroups (Table [2](#agm212005-tbl-0002){ref-type="table"}).

Finally, the funnel plot and Egger tests were used to detect publication bias of the included studies. As shown in Figure [3](#agm212005-fig-0003){ref-type="fig"}, the funnel plot was almost symmetric. In OS meta‐analysis, the *P* value of the Egger test was .120; therefore, there was no evidence for significant publication bias in the meta‐analysis.

![Funnel plot of publication bias test for overall analysis of overall survival. Each point represents a separate study](AGM2-1-39-g003){#agm212005-fig-0003}

4. DISCUSSION {#agm212005-sec-0012}
=============

Aberrant expression of miRNAs played a crucial role in the area of human carcinomas.[19](#agm212005-bib-0019){ref-type="ref"}, [20](#agm212005-bib-0020){ref-type="ref"}, [21](#agm212005-bib-0021){ref-type="ref"} Many studies have indicated that miRNAs are considered promising tumor biomarkers for prognosis and potential targets for clinical treatment.[22](#agm212005-bib-0022){ref-type="ref"} As described above, we have testified that high levels of miR‐200 family expression (predominantly miR‐200c, HR = 2.25, 95% CI 1.39‐3.64) are significantly associated with poor survival and prognostic outcomes of patients with cancers, especially in lung cancer (HR = 3.09 95% CI 1.75‐5.46). Liu et al[11](#agm212005-bib-0011){ref-type="ref"} reported that expression of miR‐200c was upregulated in non‐small cell lung cancer (NSCLC) tissues, and the patients with high miR‐200c expression had a short survival time in a cohort of 70 NSCLC patients. This might indicate that high miR‐200c plays a potential role in promoting progression of NSCLC. Some previous literatures have mentioned that miR‐200c has a binding site in the 3′ UTR of β‐tubulin III and elevated miR‐200c in cell lines decreased β‐tubulin III protein. And high tumoral β‐tubulin III was related to worse survival in NSCLC, breast and ovarian cancer.[23](#agm212005-bib-0023){ref-type="ref"} In addition, it was also shown to play a role in the regulation of mesenchymal‐epithelial transition (MET), induction of MET is important at a later point in the metastasis process and MET enables primary tumor to colonize and produce metastases in distant organs.[3](#agm212005-bib-0003){ref-type="ref"} Tejero et al[7](#agm212005-bib-0007){ref-type="ref"} recommended that only miR‐200c influenced MET/EMT in the H23, A‐549, and HCC‐44 cell lines, and Liu et al[11](#agm212005-bib-0011){ref-type="ref"} also found that overexpression of miR‐200c was associated with advanced clinical stage and lymph node metastasis. Thus, miR‐200c could be used as a potential biomarker in the prognosis of cancer patients, mainly in lung cancer. However, no statistically significant results were calculated for miR‐200a/b and miR‐429, and this might result from a relatively small number of articles about them.

In other tumor models except lung cancer, our results indicated that high miR‐200 family was not obviously associated with OS (gastric or colorectal cancer: HR = 1.00, 95% CI 0.67‐1.50; ovarian cancer: HR = 3.49, 95% CI 0.47‐25.62; others: HR = 1.63, 95% CI 0.40‐6.69). We speculated that the discordancy might result from different extent of tumor growth in cancer cells.[24](#agm212005-bib-0024){ref-type="ref"} Pacurari et al[25](#agm212005-bib-0025){ref-type="ref"} indicated that expression of miR‐200 family was rather complex during tumorigenesis, which elevated in primary tumors and downregulated in metastatic cells. Thus, it can be seen that the role of miR‐200 may differ depending on cancer type and stage. In addition, some other records showed the opposite results,[2](#agm212005-bib-0002){ref-type="ref"}, [5](#agm212005-bib-0005){ref-type="ref"}, [6](#agm212005-bib-0006){ref-type="ref"} for they exhibited that upregulated miR‐200 family level was linked to longer survival.[1](#agm212005-bib-0001){ref-type="ref"}, [4](#agm212005-bib-0004){ref-type="ref"}, [7](#agm212005-bib-0007){ref-type="ref"}, [8](#agm212005-bib-0008){ref-type="ref"}, [9](#agm212005-bib-0009){ref-type="ref"}, [10](#agm212005-bib-0010){ref-type="ref"}, [11](#agm212005-bib-0011){ref-type="ref"}, [12](#agm212005-bib-0012){ref-type="ref"}, [13](#agm212005-bib-0013){ref-type="ref"} MiR‐200 family was previously showed to inhibit the epithelial‐mesenchymal transition (EMT) and cell migration. EMT plays a key role in invasion and metastasis during carcinogenesis. Herein, these patients with high miR‐200 family expression levels might have longer survival by inhibiting EMT.

In this meta‐analysis, our stratified analyses showed that the combined HR of Asian population was 2.19 (95% CI 1.37‐3.78) and predicted poor OS. While the HR of Caucasian population was 0.94 (95% CI 0.46‐1.91), it did not exhibit an significant association with OS. This discrepancy might result from different hereditary backgrounds and environment exposure.[26](#agm212005-bib-0026){ref-type="ref"}

Although these results have indicated that miR‐200 families were promising biomarkers to predict prognosis for patients with cancers, there were several limitations in this analysis that would impact its quality. First, the number of records was only 12 with a small sample size. In particular, all studies were Asians or Caucasians, and no African population were included in the analysis. Therefore, we need more proper studies included in our meta‐analysis. Second, the relatively large heterogeneity in the present study must make caution, although it signified that the variation was not due to chance. This may arises from many factors, including tumor types, different ethnicities, or selection of subjection. The expression of miR‐200 family was detected in tumor tissues and blood samples such as plasma and serum may partly contribute to the heterogeneity. Therefore, we strongly recommend future investigations should be performed with matched cancer type, specimen, and ethnicity to confirm the conclusion. Third, the cutoff definition of miR‐200 family appeared to be different in each study, while we could not provide a clear interpretation. And then, estimates derived from different tumors are not comparable, and then inconsistent cutoff value may be the reason that provided contradictory results. Finally, as a cancer biomarker, the prognostic role was proved, besides, it remained unknown whether miR‐200 family should be used as an independent biomarker or used with several other biomarkers for predicting outcomes. Generally, further studies should be warranted to clarify this question and to provide a new novel idea for routine clinical application.

5. CONCLUSIONS {#agm212005-sec-0013}
==============

In summary, our meta‐analysis represents that high level of miR‐200 family expression is significantly associated with poor survival in patients with a variety of cancers. However, the evidence was not so convincing due to the limitations mentioned above, and further studies and more clinical investigations are required to predict the clinical outcome of patients with various carcinomas.
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